Literature DB >> 6290893

Preferential effect of gamma interferon on the synthesis of HLA antigens and their mRNAs in human cells.

D Wallach, M Fellous, M Revel.   

Abstract

Interferons produce a variety of biological effects on cells. They induce resistance to virus proliferation, inhibit cell growth, modify cell structure and differentiation, stimulate some immune functions and inhibit others. However, the different interferon (IFN) species may vary in their mechanism of action and, hence, in their relative efficiency for inducing each of the effect. IFN-gamma (type II) appears to show stronger immunoregulatory and growth inhibitory effects than antiviral effects, but this conclusion has been challenged in other reports. The aim of the present work is to compare the action of IFN-gamma and other (type I) interferons on the induction of (2'-5') oligo(A) synthetase which is probably part of the antiviral response and the induction of the histocompatibility HLA-A,-B,-C antigens. We have shown previously that the induction of both proteins is regulated by interferons at the mRNA level, but show here that IFN-gamma from stimulated human lymphocytes and from monkey cells transfected by cloned human IFN-gamma cDNA induced the HLA-A,-B,-C and beta 2-microglobulin mRNAs or proteins at concentrations over 100 times lower than those needed to induce the (2'-5')oligo(A) synthetase and the antiviral state. This difference was not found with IFN-alpha and -beta (type I).

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6290893     DOI: 10.1038/299833a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  102 in total

Review 1.  Interferons 1992. How much of the promise has been realised?

Authors:  M A Volz; C H Kirkpatrick
Journal:  Drugs       Date:  1992-03       Impact factor: 9.546

2.  Induction of auto-logous human cytotoxic T lymphocytes (CTL) from peripheral blood against tumor cells.

Authors:  T Ohno
Journal:  Cytotechnology       Date:  1997-01       Impact factor: 2.058

3.  The expression of class I major histocompatibility antigens by human retinal pigment epithelium in vitro.

Authors:  M T Benson; L Shepherd; D Cottam; J Lawry; R C Rees; I G Rennie
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1992       Impact factor: 3.117

Review 4.  The potential of interferons in malignant disease.

Authors:  K Okita; T Kaneko
Journal:  Drugs       Date:  1990-01       Impact factor: 9.546

Review 5.  Polyfunctional analysis of human t cell responses: importance in vaccine immunogenicity and natural infection.

Authors:  George Makedonas; Michael R Betts
Journal:  Springer Semin Immunopathol       Date:  2006-08-25

6.  Interferon gamma abrogates the differentiation block in v-myc-expressing U-937 monoblasts.

Authors:  F Oberg; L G Larsson; R Anton; K Nilsson
Journal:  Proc Natl Acad Sci U S A       Date:  1991-07-01       Impact factor: 11.205

7.  A longitudinal study of gamma-interferon production by peripheral blood mononuclear cells from breast- and bottle-fed infants.

Authors:  S Stephens; S W Duffy; C Page
Journal:  Clin Exp Immunol       Date:  1986-08       Impact factor: 4.330

8.  Immune interferon activates multiple class II major histocompatibility complex genes and the associated invariant chain gene in human endothelial cells and dermal fibroblasts.

Authors:  T Collins; A J Korman; C T Wake; J M Boss; D J Kappes; W Fiers; K A Ault; M A Gimbrone; J L Strominger; J S Pober
Journal:  Proc Natl Acad Sci U S A       Date:  1984-08       Impact factor: 11.205

9.  Autocrine induction of major histocompatibility complex class I antigen expression results from induction of beta interferon in oncogene-transformed BALB/c-3T3 cells.

Authors:  M K Offermann; D V Faller
Journal:  Mol Cell Biol       Date:  1989-05       Impact factor: 4.272

10.  Interferon-gamma production by peripheral blood mononuclear cells from patients with Behçet's syndrome.

Authors:  T H Bacon; F Ozbakir; C A Elms; A M Denman
Journal:  Clin Exp Immunol       Date:  1984-09       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.